Arcadia Biosciences, Inc.
RKDA
$3.15
$0.155.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.41% | 21.58% | 56.50% | 18.41% | 0.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.41% | 21.58% | 56.50% | 18.41% | 0.69% |
| Cost of Revenue | 29.55% | 42.98% | 2,680.00% | 26.87% | -5.02% |
| Gross Profit | -6.18% | 1.57% | -30.72% | 3.42% | 6.94% |
| SG&A Expenses | -20.87% | -15.71% | 56.60% | 20.32% | 29.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.12% | -4.69% | 94.58% | 22.34% | 20.90% |
| Operating Income | 25.69% | 21.39% | -126.06% | -25.98% | -38.93% |
| Income Before Tax | -340.97% | 374.45% | -805.39% | -84.98% | -41.38% |
| Income Tax Expenses | -- | -- | 14.29% | -- | -- |
| Earnings from Continuing Operations | -340.97% | 374.45% | -793.14% | -84.98% | -41.36% |
| Earnings from Discontinued Operations | -- | -- | 98.88% | 77.70% | 66.24% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -520.17% | 207.26% | -42.45% | 37.20% | 28.92% |
| EBIT | 25.69% | 21.39% | -126.06% | -25.98% | -38.93% |
| EBITDA | 25.18% | 19.59% | -139.09% | -34.02% | -43.19% |
| EPS Basic | -518.90% | 206.92% | -42.11% | 37.40% | 28.49% |
| Normalized Basic EPS | -153.08% | 192.90% | -1,913.96% | -84.38% | -167.73% |
| EPS Diluted | -1,076.96% | 206.50% | -42.11% | 37.40% | -44.91% |
| Normalized Diluted EPS | -210.26% | 192.90% | -1,913.96% | -84.38% | -129.04% |
| Average Basic Shares Outstanding | 0.31% | 0.32% | 0.24% | 0.32% | 0.32% |
| Average Diluted Shares Outstanding | -18.18% | 0.33% | 0.24% | 0.32% | 133.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |